(P018) Low-Dose-Rate, Permanent Prostate Brachytherapy Is an Effective Treatment Option for Men Less Than 55 Years Old With Low-Risk Prostate Cancer

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Prostate brachytherapy is an effective treatment for men younger than 55 years with low-risk prostate cancer. Prostate brachytherapy should be considered for all men diagnosed with low-risk prostate cancer, regardless of age.

Brian J. Moran, MD, Michelle H. Braccioforte, MS, MPH, Gregory C. Treharne, MD; Prostate Cancer Foundation of Chicago; Department of Radiation Medicine, University of Kentucky

PURPOSE/OBJECTIVE(S): To ascertain the effectiveness of low-dose-rate, interstitial, permanent prostate brachytherapy (PB) treatment in a large series of “young” patients with prostate cancer, treated at a single institution.

MATERIALS AND METHODS: A retrospective review was performed of all patients aged < 55 years treated with PB for low-risk prostate cancer between November 1997 and October 2012. Inclusion criteria were low-risk prostate cancer as defined by National Comprehensive Cancer Network guidelines of Gleason Score (GS) 6 or less, pretreatment prostate-specific antigen (PSA) < 10.0 ng/mL, and clinical stage ≤ T2a. A total of 332 patients meeting these criteria were identified; however, follow-up PSA data were available for 177 patients. Mean age was 51.3 years; mean follow-up was 4.89 years (range: 2 mo–15 yr). The mean pretreatment PSA was 5.66 ng/mL (range: 0.6–9.9 ng/mL). All patients underwent PB with 131Cs, 103Pd, or 125I. Four patients also received external beam radiotherapy (EBRT), and 12 patients received androgen deprivation therapy as part of their treatment. Progression-free survival (PFS) and overall survival (OS) were calculated from the time of PB, using Kaplan-Meier statistics.

RESULTS: In this cohort of patients, there were five PSA failures (as defined by the Phoenix definition) and four deaths (unrelated to prostate cancer). PFS was 96.2% at 5 years and 95.3% at 10 years; OS was 99.3% at 5 years and 89.4% at 10 years.

CONCLUSION: PB is an effective treatment for men aged < 55 years with low-risk prostate cancer. PB should be considered for all men diagnosed with low-risk prostate cancer, regardless of age.

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Related Content